Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer.[1] Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).[2][3] See also Abiraterone acetate.
Abiraterone, the active metabolite of abiraterone acetate, inhibits Cytochrome P450 17A1 (CYP17A1), which manifests as two enzymes, 17α-hydroxylase (IC50 = 2.5 nM) and 17,20-lyase (IC50 = 15 nM) (approximately 6-fold more selective for inhibition of 17α-hydroxylase over 17,20-lyase)[4][5] that are expressed in testicular, adrenal, and prostatic tumor tissues. See also Cytochrome P450.
(6wr1).
. Water molecules are shown as red spheres.
